HomeCompareUCBJY vs ADC

UCBJY vs ADC: Dividend Comparison 2026

UCBJY yields 0.52% · ADC yields 4.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ADC wins by $158.2K in total portfolio value
10 years
UCBJY
UCBJY
● Live price
0.52%
Share price
$150.79
Annual div
$0.79
5Y div CAGR
7.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.7K
Annual income
$111.23
Full UCBJY calculator →
ADC
Agree Realty Corporation
● Live price
4.13%
Share price
$74.97
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$178.9K
Annual income
$80,797.29
Full ADC calculator →

Portfolio growth — UCBJY vs ADC

📍 ADC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodUCBJYADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, UCBJY + ADC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
UCBJY pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

UCBJY
Annual income on $10K today (after 15% tax)
$44.56/yr
After 10yr DRIP, annual income (after tax)
$94.55/yr
ADC
Annual income on $10K today (after 15% tax)
$351.36/yr
After 10yr DRIP, annual income (after tax)
$68,677.70/yr
At 15% tax rate, ADC beats the other by $68,583.15/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of UCBJY + ADC for your $10,000?

UCBJY: 50%ADC: 50%
100% ADC50/50100% UCBJY
Portfolio after 10yr
$99.8K
Annual income
$40,454.26/yr
Blended yield
40.52%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

UCBJY
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
6.1
Piotroski
8/9
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+8.1% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

UCBJY buys
0
ADC buys
0
No recent congressional trades found for UCBJY or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricUCBJYADC
Forward yield0.52%4.13%
Annual dividend / share$0.79$3.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR7.3%40.4%
Portfolio after 10y$20.7K$178.9K
Annual income after 10y$111.23$80,797.29
Total dividends collected$810.00$156.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: UCBJY vs ADC ($10,000, DRIP)

YearUCBJY PortfolioUCBJY Income/yrADC PortfolioADC Income/yrGap
1← crossover$10,756$56.25$10,990$580.36$234.00ADC
2$11,570$60.67$12,301$860.26$731.00ADC
3$12,445$65.44$14,104$1,298.62$1.7KADC
4$13,387$70.59$16,691$2,008.16$3.3KADC
5$14,400$76.15$20,580$3,205.09$6.2KADC
6$15,490$82.14$26,754$5,330.02$11.3KADC
7$16,663$88.60$37,196$9,345.14$20.5KADC
8$17,925$95.58$56,244$17,523.09$38.3KADC
9$19,283$103.11$94,286$35,736.21$75.0KADC
10$20,744$111.23$178,949$80,797.29$158.2KADC

UCBJY vs ADC: Complete Analysis 2026

UCBJYStock

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Full UCBJY Calculator →

ADCREIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this UCBJY vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

UCBJY vs SCHDUCBJY vs JEPIUCBJY vs OUCBJY vs KOUCBJY vs MAINUCBJY vs NNNUCBJY vs EPRTUCBJY vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.